Novavax, Rovi end flu vaccine development plan

TEL AVIV, Israel — Novavax Inc. announced Feb. 8 that it ended talks aimed at a collaboration with Rovi Pharmaceuticals of Madrid to develop Novavax's viruslike particle vaccines against influenza in Spain.

The companies couldn't come to terms on the collaboration and couldn't find committed funding for the program, Novavax officials said.

The biotech company based in Rockville, Md., also said it's free to find a new partner for its vaccine-development efforts in Europe. Meanwhile, Novavax is continuing plans to develop its vaccines in Mexico, India and the United States.